Clinical practice of epidermal growth factor receptor-tyrosine kinase inhibitor targeted drugs combined with gadolinium oxide nanoparticles in the treatment of non-small cell lung cancer

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer

(2021) Sara S. Fois et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations

(2021) Joydeb Majumder et al.   Pharmaceutics

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

(2020) Kohsuke Isomoto et al.   CLINICAL CANCER RESEARCH

Lung Cancer 2020

(2020) Brett C. Bade et al.   CLINICS IN CHEST MEDICINE

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)

(2020) Yinxue Song et al.   BIOMEDICINE & PHARMACOTHERAPY

Affibody-Modified Gd@C-Dots with Efficient Renal Clearance for Enhanced MRI of EGFR Expression in Non-Small-Cell Lung Cancer

(2020) Yongyi Wu et al.   International Journal of Nanomedicine

Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)—development and in-vitro efficacy

(2020) Rasha S. Elbatanony et al.   Drug Delivery and Translational Research

Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC

(2020) Xiuning Le et al.   Journal of Thoracic Oncology

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives

(2020) Evgeny N. Imyanitov et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Correlation between effects of the particle size and magnetic field strength on the magnetic hyperthermia efficiency of dextran-coated magnetite nanoparticles

(2020) Zhila Shaterabadi et al.   Materials Science & Engineering C-Materials for Biological Applications

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

(2019) Ana C.Z. Gelatti et al.   LUNG CANCER

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

(2019) Jeffrey D. Bradley et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

(2018) J Remon et al.   ANNALS OF ONCOLOGY

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

(2018) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset

(2018) Byoung Chul Cho et al.   Journal of Thoracic Oncology

Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer

(2017) Misako Nagasaka et al.   Expert Review of Anticancer Therapy

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy

(2017) Lais Osmani et al.   SEMINARS IN CANCER BIOLOGY